Terumo Cardiovascular Systems Expands Presence in US Cardiac Surgery Market

    ANN ARBOR, Mich., July 5 /PRNewswire/ -- Terumo Cardiovascular Systems
 Corporation (Terumo CVS) and Fresenius HemoCare GmbH announced today that they
 have signed a distributor and license agreement appointing Terumo CVS the
 exclusive distributor for the Fresenius C.A.T.S systems in the U.S.  The
 agreement takes place one year after Terumo Medical Corporation acquired 3M's
 global cardiovascular business to form the subsidiary, Terumo CVS.
     Terumo CVS currently manufactures, markets, and sells CAPIOX, Sarns, and
 CDI brand products used in cardiac surgery to the U.S. and other global
 markets.  The Fresenius C.A.T.S system is used primarily in cardiac surgery,
 as well as orthopedic surgery and trauma centers.  The agreement will take
 effect August 1, 2000.
     Terumo Cardiovascular Systems is a subsidiary of Terumo Medical
 Corporation, the U.S. subsidiary of Terumo Corporation of Japan.  Terumo
 Corporation is a premier global medical company with 1999 annual sales of
 approximately $1.6 billion.  Terumo Corporation manufactures, markets and
 sells a wide range of medical products including syringes, needles, catheters,
 and blood bags.  Terumo Cardiovascular Systems is headquartered in Ann Arbor,
 Michigan with manufacturing operations in Ann Arbor, as well as Elkton,
 Maryland; Ashland, Massachusetts; and Tustin, California.
     Fresenius HemoCare is a company of the Fresenius Health Care Group, which
 achieved world-wide sales in 1999 of approx. 5 billion Euros (+15%) with some
 43,000 employees, and net income of 203 million Euros (+39%).  Fresenius
 HemoCare provides a wide range of products and services for blood transfusion
 and cell separation, infusion of solutions and pharmaceuticals.  The company
 also has expertise in cancer therapy and innovative adsorber processes for the
 treatment of blood outside the body.
 
 

SOURCE  Terumo Cardiovascular Systems